We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ERYFF market cap is 0. The company's latest EPS is EUR -0.7579 and P/E is -93.71.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 5.28M | 3.72M | 4.18M | 6.65M | 1.33M |
| Operating Income | -64M | -68.83M | -56.52M | -27.15M | -23.66M |
| Net Income | -62.66M | -73.3M | -53.8M | -228k | -23.49M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 118.55M | 80.4M | 66.77M | 45.81M | 51.31M |
| Total Liabilities | 32.99M | 53.86M | 43.92M | 22.32M | 25.7M |
| Total Equity | 85.56M | 26.54M | 22.85M | 23.49M | 25.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -43.31M | -51.72M | -56.77M | -31.76M | -24.43M |
| Investing | -19.84M | -1.48M | -345k | 38.13M | 172k |
| Financing | 39k | 25.45M | 44.71M | -1.77M | -3.72M |
| Market Cap | 0 |
| Price to Earnings Ratio | -93.71 |
| Price to Sales Ratio | 1.66k |
| Price to Cash Ratio | 210.12 |
| Price to Book Ratio | 85.93 |
| Dividend Yield | - |
| Shares Outstanding | 30.99M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | PHAXIAM Therapeutics SA (PK) |
| Address |
60 avenue rockefeller lyon, rhone 69008 |
| Website | https://www.erytech.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
